SAN RAMON, Calif.--(BUSINESS WIRE)--Nov 8, 2022--
Today, the first membership-driven industry alliance advancing radio-frequency identification (RFID) technology in pharmaceuticals announced its rebrand to UnitVisID Alliance, as the new name for the DoseID Consortium. The name change reflects the organization’s commitment and mission to ensure the quality, performance, and interoperability of RFID-tagged pharmaceutical products as they move through the supply chain – from manufacturing to patient use.
The confluence of the COVID-19 pandemic, drug shortages, and staff shortages have accelerated RFID technology adoption. Emergen Research forecasts that the market for RFID in healthcare will reach almost US $15 billion in 2028 globally from $4.24 billion in 2020.
With advancements in technology and innovation, RFID-tagged pharmaceutical products in the healthcare industry present opportunities to improve inventory management and, ultimately, better patient outcomes. Currently, UnitVisID is used by more than 1,000+ hospitals and healthcare organizations, and more than 210 million RFID-tagged products utilizing the UnitVisID platform have been scanned, more than any other RFID system in the US healthcare space.
“We've realized the many benefits of RFID in healthcare, and its massive adoption is a testament that we are now at a tipping point,” said Tim Kress-Spatz, President at UnitVisID Alliance. “The rebrand reflects this change, and to really tackle the challenges of shortages, recalls, workflow inefficiencies, and lack of interoperability, it requires a whole of industry approach from the entire healthcare supply chain.”
The Alliance provides a unified approach with research, tools, and resources for the healthcare industry that ensures RFID-tagged pharmaceutical products work in all downstream systems in hospitals and healthcare systems. UnitVisID is open to hospitals and industry organizations. Current industry members span the pharmaceutical manufacturing ecosystem and include RFID companies, pharmaceutical manufacturers, 503B outsourcing facilities, technology and automation vendors, label converters, and service suppliers.
Hospitals and technology providers interested in joining the UnitVisID Alliance, can visit unitvisid.com/membership/join/ to learn more about membership benefits.
The UnitVisID Alliance membership represents many of today’s leading companies in the pharmaceutical manufacturing ecosystem. Alliance members include Avery Dennison Corporation, Baxter, CCL Healthcare, George Schmitt & Co., Hikma, Identiv, Impinj, Intelligent Label Solutions, International Medical Industries, Inc., Kit Check, MPI Label Systems, Nephron, Omnicell, Sandoz, SCHOTT Pharmaceutical Systems,Schreiner MediPharm, and Tageos.
About UnitVisID Alliance
UnitVisID is the first open, member-driven Alliance advancing the use of radio-frequency identification (RFID) tagged pharmaceutical products in healthcare. The Alliance brings together the leading companies in the pharmaceutical manufacturing ecosystem to lead, collaborate, and develop RFID specifications that ensure accuracy, performance, and interoperability. Members include hospitals, pharmaceutical manufacturers, 503B outsourcing facilities, automation/technology vendors, label converters, and inlay manufacturers. UnitVisID is the #1 choice used by more than 1,000+ hospitals and healthcare organizations. More than 210 million RFID-tagged products utilizing the UnitVisID platform have been scanned – exponentially more than any other RFID system in the US healthcare space. Visit us at www.unitvisid.com
View source version on businesswire.com:https://www.businesswire.com/news/home/20221108005045/en/
Media@UnitVisID.com
KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: TECHNOLOGY BIOTECHNOLOGY HEALTH OTHER HEALTH PHARMACEUTICAL OTHER SCIENCE MEDICAL DEVICES SOFTWARE MANAGED CARE HOSPITALS HARDWARE SCIENCE DATA MANAGEMENT MEDICAL SUPPLIES
SOURCE: UnitVisID Alliance
Copyright Business Wire 2022.
PUB: 11/08/2022 08:45 AM/DISC: 11/08/2022 08:47 AM
http://www.businesswire.com/news/home/20221108005045/en